1SCHROEDER W ,Ghobrial L ,Gandhi P. Possible mechanisms of drug-induced aspirin and clopidogrel resistance [J].Journal of Thrombosis and Thrombolysis, 2006,22 ( 2 ) : 139- 150.
2COZZA K L, ARMSTRONG S C, OESTER HELD J R. Drug interactions by medical specialty. In:Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450s, UGTs, P-Glycoproteins [M]. 2nd ed. Washington D C: American Psychiatric Pub, 2003,167-396.
3ZEVIN S, BENOWITZ N L. Drug Interactions with Tobacco Smoking : An Update[J]. Clinical Pharmacokinetics, 1999,36 : 425-438.
4DE LEON J, DIAZ F J, ROGERS T, et al. A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers [J]. Prog Neuropsychopharmaeol Biol Psychiatry, 2003,27 (1) : 165-171.
5NGUYEN M ,CHUNG E P. Telithromycin :The first ketolide antimicrobial [J]. Clinical Therapeutics, 2005,27 (8) : 1144-1163.
6SLAUGHTER R L, EDWARDS D J. Recent advances: the cytochrome P450 enzymes [J].Ann Pharmacother, 1995,29 : 619-624.
7WEINSHILBOUM R. Inheritance and Drug Response [J]. N Engl J Med,2003,348(6): 529-537.
8[Anonymous] Special report: genotyping for cytochrome P450 polymorphisms to determine drug-metabolizer status[J]. Technol Eval Cent Asses Program Exec Summ, 2004,19 : 1-2.
9MICHALETS E L. Update :clinically significant cytochrome P-450 drug interactions [J]. Pharmacotherapy, 1998,18 : 84-112.
10HUANG S M, TEMPLE R, THROCKMORTON D C, et al. Draft Guidance for Industry : Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labling [J]. Clin Pharmacol Ther, 2007,81 (2) : 298-304.
